TCR V beta 5.1/5.2 Monoclonal Antibody (MR9-4), PE, eBioscience™, Invitrogen™

Description

• Description: This MR9-4 monoclonal antibody reacts with the mouse T cell receptor (TCR) V beta 5.1/5.2 chain
• Composed of an alpha and beta chain, TCR specificity is typically determined by Va, Ja, Vb, Db, and Jb gene rearrangement
• The MR9-4 antibody recognizes the V beta 5.1 and 5.2 chains on T cells from mouse strains with the b haplotype of the Tcrb gene, including C57BL/6, B10, and C58/J
• V beta 5.1 and 5.2 are deleted in mouse strains that express MHC Class II I-E, including Balb/c, C3H, and DBA/2
• Reports also indicate that V beta 5+ T cells recognize the OVA peptide
• Applications Reported: This MR9-4 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This MR9-4 antibody has been tested by flow cytometric analysis of mouse splenocytes
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser
• The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC) class II molecules is essential for an effective adaptive immune response
• TCR recognition of self-peptides has been linked to autoimmune disease
• Mutant self-peptides have been associated with tumors
• Engagement of TCRs by a family of bacterial toxins know as superantigens has been responsible for toxic shock syndrome
• Autoantibodies to V beta segments of T cell receptors have been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
• The autoantibodies block TH1-mediated inflammatory autodestructive reactions and are believed to be a method by which the immune system compensates for disease
• Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single positive, SP)
• A small number of T cells lack both CD4 and CD8 (double negative, DN)
• Increased percentages of alpha-beta DN T cells have been identified in some autoimmune and immunodeficiency disorders
• Gamma-delta T cells are primarily found within the epithelium
• They show less TCR diversity and recognize antigens differently than alpha-beta T cells
• Subsets of gamma-delta T cells have shown antitumor and immunoregulatory activity.